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Abstract: In this work, we proposed a process to select informative genetic variants for identifying
clinically meaningful subtypes of hypertensive patients. We studied 575 African American (AA)
and 612 Caucasian hypertensive participants enrolled in the Hypertension Genetic Epidemiology
Network (HyperGEN) study and analyzed each race-based group separately. All study participants
underwent GWAS (Genome-Wide Association Studies) and echocardiography. We applied a variety of
statistical methods and filtering criteria, including generalized linear models, F statistics, burden tests,
deleterious variant filtering, and others to select the most informative hypertension-related genetic
variants. We performed an unsupervised learning algorithm non-negative matrix factorization
(NMF) to identify hypertension subtypes with similar genetic characteristics. Kruskal–Wallis tests
were used to demonstrate the clinical meaningfulness of genetic-based hypertension subtypes.
Two subgroups were identified for both African American and Caucasian HyperGEN participants.
In both AAs and Caucasians, indices of cardiac mechanics differed significantly by hypertension
subtypes. African Americans tend to have more genetic variants compared to Caucasians; therefore,
using genetic information to distinguish the disease subtypes for this group of people is relatively
challenging, but we were able to identify two subtypes whose cardiac mechanics have statistically
different distributions using the proposed process. The research gives a promising direction in using
statistical methods to select genetic information and identify subgroups of diseases, which may
inform the development and trial of novel targeted therapies.
Keywords: hypertension; variable selection; subtype identification; clustering algorithm; NMF

1. Introduction
Hypertension is a heterogeneous condition with various subtypes that differ in pathophysiology
and age distribution [1]. It has been shown to have subtypes such as borderline isolated systolic
hypertension (systolic ≥140, diastolic <90 mmHg), definite isolated systolic hypertension (systolic
≥160, diastolic <90 mmHg), isolated diastolic hypertension (systolic <160, diastolic ≥90 mmHg),
and definite hypertension (systolic ≥160 and diastolic ≥90 mmHg or hypertensives on treatment) [2].
The discovery of hypertension phenotypic heterogeneity leads us to pursue the next question of
identifying subtypes of hypertension based on genetic information.
Development of high throughput technologies, such as genome-wide sequencing and SNP-array
approaches give researchers promising directions to reveal disease genes and mechanisms for further
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application to new therapeutic targets. To better achieve effectiveness, it is important to select
informative genetic information for down-stream analysis such as clustering and classification.
Different machine learning and statistical learning algorithms have been applied to select useful
information and group together patients with similar phenotypic and genetic performance. Supervised
learning can be applied to find out disease related variants. The support vector machine was used to
determine the SNP subset which has the highest classification accuracy [3]. Sequence kernel association
test (SKAT) was developed to find out association between the genetic region and a continuous or
dichotomous trait while adjusting for covariates [4]. Unsupervised learning, on the other hand, is to
learn the intrinsic structures of selected informative genetic data to derive novel subtypes of disease.
Brunet, Tamayo et al. applied non-negative matrix factorization to solve three problems in elucidating
cancer subtypes [5]. Cai, Huang et al. modified K-means clustering in analysis of SAGE data [6].
Shah, Katz et al. used unbiased hierarchical cluster analysis of phenotypic and penalized model-based
clustering, to define and characterize mutually exclusive groups making up a novel classification of
heart failure with preserved ejection fraction [7].
In this paper, we use a generalized linear model to limit the scope of variants to hypertension
related ones and then apply different criteria to further filter informative SNPs to reduce the false
positive rate. In addition to common genetic filters such as rare variants and deleterious variants,
we also make a generalization of F-ranking statistics. F-statistics describe the level of a variant’s
variability among different population classes. Variants with higher F statistics have more capability
in distinguishing diseases status. Therefore, we can use F statistics as a metrics to measure the
relatedness of a variant with hypertension status. For the choice of unsupervised learning algorithm,
various methods have been developed to cluster samples with similar genetic information. In this
paper, we use non-negative matrix factorization (NMF) which can capture the underlying correlation
structure of genetic data, while at the same time, the positive components of output can give a better
interpretation of the results.
2. Materials and Methods
Figure 1 shows the proposed procedure to select informative genetic variants and to identify
subgroups of hypertension patients using unsupervised learning algorithms.

Figure 1.
Flow chart of the procedure to select informative variants and identify
hypertension subgroups.
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2.1. Using Logistic Regression to Filter Hypertension Related Variants
To divide the patients with hypertension into subgroups using genetic information, variants which
have no association with hypertension status need to be filtered out. This is built on the assumption
that variants which are correlated with the hypertension status will also function on further dividing
hypertension patients into subgroups. The classical logistic regression model is constructed to reflect
the relationship between the variants and hypertension status. Factors such as age, gender, and BMI
are known to be related to hypertension. Therefore, we take these covariates into consideration to
adjust the confounding effects.
Assume the number of subjects/patients with both genetic and phenotypic information is n and
the number of variants in the pool (number of variants fed into the regression model) is P. For the
ith subject (i = 1, 2, ..., n), yi denotes his/her hypertension status (1 = with hypertension, 0 = without
hypertension), Xi = ( Xi1 , Xi2 , Xi3 ) is a vector representing the three covariates, and Gip denotes the pth
genetic variant for ithe subject where p = 1, 2, ..., P, taking values of 0, 1, or 2. The logistic model is
applied to each of the P variants:
0
Xi + β ip Gip
logit[ P(yi = 1)] = α0ip + αip

(1)

Variants with p-values less than a certain cutoff value are selected. We set different cutoff values
to test the robustness. This basic filtration gives us the variants related to the hypertension status.
However, many of them have a negative effect on hypertension status, which means that they help
control the hypertension. Since our purpose was to find the informative variants who can further
divide the hypertension patients into subgroups, we only considered those variants which have
positive effect on hypertension status. Therefore, only variants with the positive effect are selected.
2.2. Using F-Statistics to Rank the Selected Variants
Single nucleotide polymorphism (SNP) has three characteristics [3]: (1) it is common in the human
genome (occurs every 100–300 bases); (2) about 75% variations are from cytosine (C) to thymine (T);
(3) it is stable from generation to generation. Due to these characteristics, genetic variants can be used
on population classification. Variants can be ranked and selected based on certain measurements
which reflect their capability of population classification. In this paper, we generalize the F Statistics
which were originally used in population classification [3,8] to rank the variants selected from logistic
regression. Variants with higher F statistics are more related to hypertension disease status. We add
variants in decreasing order of F statistics to the unsupervised clustering model.
We assume that the SNPs which have the higher capability of distinguishing the hypertension
status also play an important role in subtyping patients with hypertension. In our study, there are
two sub-populations (with or without hypertension). Each feature is expressed as an SNP, and the F
statistics is defined as:
F = Var ( p)/( p̄ × q̄)
(2)
p +p

where p̄ = 1 2 2 , q̄ = 1 − p̄ represent the two alleles’ mean frequencies in two population classes.
p1 and p2 represent the frequencies of one allele for the first and the second population, respectively.
2
2
var ( p) = ∑cc=
=1 ( pc − p̄ ) /2.
2.3. Taking into Account the Impact of Rare Variants on Complex Diseases
Genome-wide association studies (GWASs) have identified over 1000 genetic loci influencing
blood pressure with multiple systems and tissues implicated [9]. Common variants are widely accepted
to have effect on complex disease. However, there are arguments about the effect of rare variants on
explaining the trait heritability. As researchers have not derived the determined variants associated
with the hypertension status, we apply the filtering process to both of rare variants and common
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variants. We use the gnomAD database as reference for selection of rare variants. SNPs with frequency
less than 1% in the gnomAD database are selected from our dataset as rare genetic variants.
2.4. Aggregating Variants within the Same Genetic Region to Increase Power
Many variants in our dataset have low frequencies; therefore, the effectiveness of applying them
directly to the clustering method is under powered [10,11]. A logical approach is to use the burden test
which applies clustering methods to the summarizing statistics that represent the variants within the
same genetic region [10–15]. Clustering and testing on the cumulative effects can increase the power.
The basic assumption for the burden test is that impact of variants within the same genetic region
on the phenotype or disease status has the same direction and scale. However, this assumption can
yield large bias. In our case, in the same gene, some of the variants have negative effect on hypertension
status, while others have positive effect. To deal with this problem while increasing the test power,
we aggregate variants with positive effect size only. These variants influence the hypertension status
with the same direction and scale.
2.5. Selecting Deleterious Variants
Even though variants selected from logistic model are correlated with the hypertension status,
they may be synonymous SNPs, which means that their change will not cause an amino acid to change.
The noise brought by these synonymous SNPs may weaken the real signal. ANNOVAR gene-based
annotation is used to select deleterious variants. Three databases (refGene, knownGene, ensGene) are
used as references. If a variant is deleterious in any one of the three databases, then it is selected. In our
case, nonsynonymous, stopgain, and stoploss variants are defined as deleterious. We use the African
Americans as an example to show the number of different types of variants (please refer to Table 1).
Table 1. Summary of number of variants with different functions using three gene annotation databases
for African American patients.
SNP Array

ANNOVAR Gene-Based Annotation

AA

refGene

knownGene

ensGene

nonsynonymous SNP

10,554

11,073

11,404

stopgain

90

110

117

stoploss

12

17

17

synonymous SNP

17,802

18,231

18,511

unknown

553

10

9

2.6. Using NMF to Cluster Hypertensive Patients into Subgroups
Different unsupervised learning algorithms have been used to identify disease subtypes.
The commonly used algorithms include hierarchical clustering (HC), principal component analysis
(PCA), self-organizing map (SOM), etc. However, these methods have limitations when being applied
to genetic data. HC has stringent tree structures and is very sensitive to the choice of dissimilarity
measurement. PCA requires matrices to be orthogonal which results in difficulty of interpretation for
the decomposition. SOM is unstable to the choice of initial conditions. In this paper, we use nonnegative
matrix factorization (NMF) to identify subgroups of hypertension patients. As we are focusing on
count data that are by definition nonnegative, we use NMF instead of other grouping methods such as
k-means or principal component analysis (PCA) that do not have a built-in nonnegative constraint.
NMF can also capture the underlying structure of genetic data and at the same time, it organizes both
the genetic information and samples, to provide biological insight.
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Given a matrix A of size N × M, N represents the number of variants (or genes in the aggregation
approach), M represents the number of patients with hypertension. With a desired rank K, NMF is
used to compute an approximation of A ∼ W H, where W (size N × K) and H (size K × M) are
non-negative matrices. Each column of W defines the coefficients of variants in each corresponding
meta-variant (or meta-gene with aggregation). H represents the level of meta-variants (or meta-genes)
in each sample. We cluster samples into subgroups based on the level of meta-variants (or meta-genes).
For example, sample m (1, 2, ..., M) belongs to cluster k(1, 2, ..., K ) with the highest level of meta-variant
(meta-gene) k in matrix H.
To capture the subclass, we use the “brunet” algorithm [5] which is based on iteratively updating
divergence-based equations related to Poisson likelihood function. Since NMF has stochastic property,
we can use the Cophenetic correlation coefficient (CCC) to determine the best rank K. The method is
originally proposed by [5]. The basic assumption is that if rank K fits the data well, sample distribution
should be similar under different runs. The cophenetic correlation coefficient summarizes the
consistency of sample distribution under different initials. In a perfect case, the value of CCC is
1 (0 ≤ CCC ≤ 1). Best rank K is determined by high CCC. In this real-data analysis, CCC has the
highest value when we divide the hypertension patients into two clusters both for African American
and Caucasian cohorts.
2.7. Using Kruskal–Wallis Test to Evaluate the Efficiency of Different Methods
Nine phenotypic variables (please refer to Table 2 for detailed information) are used to examine the
clinical significance of genetic-based hypertension subgroup identification. It is clinically meaningful
if distributions of the phenotypic variables are significantly different among different subgroups.
Since they are non-normally distributed within samples of different sizes, we apply Kruskal–Wallis
test which is a non-parametric rank test used to compare two or more independent samples of equal
or unequal sample sizes.
3. Results
We first introduce the study population. Then, we present the results for different combinations
of filtration methods to select the most important and relevant variants which are used to cluster
hypertensive patients into subgroups.
3.1. Population of Study
Our study subjects were enrolled in the Hypertension Genetic Epidemiology Network
(HyperGEN), which is part of the National Institutes of Health Family Blood Pressure Program.
It is a cross-sectional study consisting of individuals with hypertension, their siblings, and a
random sample of normotensives who were all recruited from four cities in the United States.
HyperGEN aims to identify and characterize the genetic basis of familial hypertension. Complete
details of the HyperGEN study are reported in Williams et al. [16]. Both Caucasian and African
American HyperGEN participants underwent GWAS with Affymetrix 5.0 and 6.0 arrays, respectively.
For quality control, we removed monomorphic markers, insertion/deletion variants, and single
nucleotide polymorphisms (SNPs) with missing rate >5% or Mendelian errors. For imputation, we
used Minimac with 1000 G Phase I Integrated Release Version 3 Haplotypes (2010-11 data freeze,
2012-03-14 haplotypes) that contains haplotypes of 1092 individuals of all ethnic backgrounds and
excludes monomorphic and singleton sites. Participants also underwent systematic echocardiography
(cardiac ultrasound) as described in detail by Aguilar et al. [17]. These echocardiograms are
initially recorded on VHS videotape format and subsequently digitized to DICOM format after
which they underwent speckle-tracking analysis for measurement of indices of cardiac mechanics.
The measurements from the HyperGEN echocardiograms that reflect cardiac mechanics are outcome
variables (only nine phenotypic variables are available), as listed in Table 2. Indices of cardiac
mechanics obtained by speckle-tracking echocardiography are more sensitive measures of intrinsic
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cardiomyocyte function [18] compared to conventional cardiac function measures such as ejection
fraction. Furthermore, indices of cardiac mechanics are thought to be subclinical measures of
myocardial dysfunction that occur during the transition from risk factors (e.g., hypertension, obesity,
diabetes, coronary disease) to overt heart failure [19,20]. Markers of maladaptive cardiac structural
remodeling such as left ventricular hypertrophy (i.e., increased left ventricular mass) can also impact
indices of cardiac mechanics [17].
Of the 1258 African American HyperGEN participants with ExomeChip data, 921 had adequate
echocardiograms for quantitation of indices of cardiac mechanics. Of these 921 participants, 575 had
a history of hypertension. There were 2,846,152 variants in 38,189 genes or between-gene regions.
Of the 1270 Caucasian HyperGEN participants, 1181 had adequate echocardiograms for quantitation
of indices of cardiac mechanics. Of these 1181 participants, 612 had hypertension (2,354,081 variants
in the Caucasians). Our goal is to cluster hypertensive participants using genetic information into
clinically meaningful subtypes in the HyperGEN African American and Caucasian cohorts separately.
Table 2. Description of 9 phenotypic/outcome variables that are used to examine the significance of
genetic-based hypertension subtype identification.
Abbreviation

Full Name

elateral

Lateral e’ velocity

eseptal

Septal e’ velocity

gcs

Global circumferential strain

gls

Global longitudinal strain

grs

Global radial strain

sr_a

strain rate-atrial

sr_e

strain rate-early diastlic

sr_s

strain rate-early systolic

sseptal

Septal s’ velocity

slateral

Lateral s’ velocity

Description
Left ventricular early diastolic relaxation velocity,
measured at the lateral mitral annnulus
in the apical 4-chamber view
Left ventricular early diastolic relaxation velocity,
measured at the septal mitral annnulus
in the apical 4-chamber view
Left ventricular circumferential strain,
measured in the parasternal short axis view
Left ventricular longitudinal strain,
measured in the apical 4-chamber view
Left ventricular radial strain,
measured in the parasternal short axis view
Left ventricular late (atrial) diastolic strain rate,
measured in the apical 4-chamber view
Left ventricular early diastolic strain rate,
measured in the apical 4-chamber view
Left ventricular systolic strain rate,
measured in the apical 4-chamber view
Left ventricular systolic longitudinal velocity,
measured at the septal mitral annulus
in the apical 4-chamber view
Left ventricular systolic longitudinal velocity,
measured at the lateral mitral annulus
in the apical 4-chamber view

3.2. Comparisons of Clustering Results for Different Methods
For both African American and Caucasian cohorts, two hypertension subtypes are identified.
Table 3 summarizes different combinations of filtering methods and the corresponding p-values from
Kruskal–Wallis test for comparing distributions of phenotypic variables between two subgroups.
The first combination is designed to explore the influence of rare variants on hypertension status.
The number of rare variants for African American and Caucasian are 73,738 and 4925, respectively.
Of these, 1872 and 141 have positive effect size in logistic regression. We use F-statistics to rank all rare
variants, choose certain cutoff numbers of variants and intersect them with the variants which have
positive effect size. This step helps to reduce the false positive rate of variants selected from logistic
regression model. Since the signal for rare variants is low, we aggregate variants within the same

Genes 2020, 11, 1265

7 of 13

genetic region before inputting them into NMF model. For the African American cohort, the best cutoff
percentage for F ranked rare variants is 2% which yields the highest clustering efficiency. The number
of informative variants left is 472 covering 306 genetic regions. Six phenotypic variables are statistically
different in their distributions between the two subgroups. However, there are no significant variables
under different cutoff percentages for Caucasian cohort.
Since there are arguments about the influence of rare variants and common variants on complex
diseases. We revise the first combination by considering all variants instead of just rare variants.
The number of statistically significant variants with positive effect size from logistic regression are
83,648 and 67,450 for African American and Caucasian cohorts, respectively. Since the number of total
variants sequenced is too large, we use F statistics to rank the positively effective variants and find
the best cutoff percentage. Other steps are the same as for the first combination. The best clustering
result is that four phenotypic variables are significantly different between two subgroups for African
American patients and six for Caucasian patients. However, the number of variants used to achieve
the highest clustering efficiency for two cohorts are significantly different in scale. The best cutoff
percentage for African American is 15% with 12,555 variants, while for Caucasian the best cutoff is 1%
with only 675 variants.
Since using F-statistics requires subjective judgment on the choice of best cutoff percentage of
ranked variants and the number of variants selected is not consistent in two cohorts, we decide to
apply another filtering method. First, we select deleterious variants whose changes affect the amino
acids. However, not all deleterious variants are correlated with hypertension. Therefore, in the second
step, we still need to build logistic model to filter out uncorrelated variants. The last four rows of
Table 3 summarize the main components of this combination. To test the sensitivity of clustering
efficiency, we apply different cutoff p-values to select significant variants from logistic model. It is
noticed that the number of variants and covered genetic regions are similar, with one variant per region
on average. Therefore, the combinations without gene aggregation are also conducted. In this special
case, doing so will not only keep all the original genetic information but also ensures the test power.
Table 3 shows that gene aggregation brings no benefit to the clustering efficiency; this may be due to
the relatively high MAF of selected deleterious variants with positive effect size and the low average
number of variants per genetic region. Therefore, we use the results from combinations without gene
aggregation. Under different cutoff p-values (4th and 6th rows in Table 3), the number of statistically
significant variables in African American cohort stays the same. For Caucasian cohort, six variables are
significantly different in their distribution between two subgroups under 0.05 p-value cutoff. When we
increase the cutoff p-value to 0.1, the number of significant variables increases to seven with six of them
detected with cutoff p-value of 0.05. Therefore, the clustering results are robust to the choice of cutoff
p-values. Another important thing to note is the change of cluster allocation of hypertensive patients
under different cutoff p-values (listed in Table 4). The number of African American patients whose
allocation does not change under two cutoff p-values is 353 out of 575 total AA hypertension patients.
In Caucasian cohort, only one patient changes his/her cluster allocation. The clustering allocation of
African American patients is sensitive to the choice of cutoff p-values, while not for Caucasian cohort.
As is known, African American tend to have more genetic variants compared to Caucasian, therefore,
using genetic information to distinguish the disease subtypes for African Americans is relatively
challenging. We also conduct a Kruskal–Wallis test on NMF decomposition matrix H. The results
show that patients whose allocation change under two different cutoff p-values are those with similar
entries in the corresponding columns of H, which indicates these patients have ambiguous clustering
allocation using NMF method.
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Table 3. Summary of Kruskal–Wallis test results for each phenotypic variable using different
combination of filtrations.
Methods p-Value a
(AA/Caucasian)
Logistic (0.05) + F +
Rare b + geneaggr c
Logistic (0.05) + F +
All d + geneaggr
Logistic (0.05) + del e +
geneaggr

Phenotypic Variables
Elateral Eseptal gcs
gls
grs
sr_a
sr_e
sr_s
Sseptal
0.11
0.07
0.97
0.02
0.80
0.07
0.06
0.01
0.00
/>0.1
/>0.1
/>0.1 />0.1 />0.1 />0.1 />0.1 />0.1
/>0.1
0.51
0.32
0.05
0.07
0.18
0.04
0.11
0.08
0.16
/0.04
/0.00
/0.03 /0.01 /0.28 /0.44 /0.05 /0.18
/0.02
0.97
0.68
0.73
0.01
0.76
0.19
0.62
0.01
0.11
/0.04
/0.01
/0.65 /0.03 /0.39 /0.02 /0.10 /0.08
/0.09
0.76
0.30
0.42
0.02
0.74
0.48
0.64
0.01
0.29
Logistic (0.05) + del
/0.05
/0.01
/0.65 /0.03 /0.39 /0.02 /0.10 /0.08
/0.09
Logistic (0.1) + del +
0.49
0.11
0.97
0.16
0.72
0.13
0.29
0.30
0.39
geneaggr
/0.07
/0.02
/0.63 /0.03 /0.37 /0.01 /0.14 /0.09
/0.11
0.77
0.82
0.89
0.02
0.65
0.21
0.45
0.02
0.15
Logistic (0.1) + del
/0.03
/0.02
/0.73 /0.02 /0.32 /0.02 /0.08 /0.06
/0.06
[a] The first row shows the name of 9 phenotypic variables; [b] “Rare” means only rare variants are
used; [c] “geneaggr” means aggregating variants within the same genetic region; [d] “All” means all
variants are used; [e] “del” means deleterious variants.
Table 4. The first half is the summary of number of significant phenotypic variables and number of
variants selected to do the clustering analysis using different combinations of filtrations. The second
half summarizes the number of hypertensive patients in each subgroup under different combinations
of filtrations.

Methods/Number of
Significant Phenotypic Variables

Logistic (0.05) + F + Rare + geneaggr
Logistic (0.05) + F + All + geneaggr
Logistic (0.05) + del + geneaggr
Logistic (0.05) + del
Logistic (0.1) + del + geneaggr
Logistic (0.1) + del

Number of Significant
Phenotypic Variables
(Number of Variants;
Number of Genetic Regions
If with Geneagg)
African American Caucasian
6 (472)
0
4 (12,555)
6 (675)
2 (370; 339)
6 (217; 213)
2 (370)
6 (217)
0 (735, 643)
6 (467, 379)
2 (735)
7 (467)

Number of Hypertensive
Patients in Each Cluster
African American

Caucasian

430/145
318/257
445/130
398/177
273/302

583/29
485/127
485/127
486/126
484/128

3.3. Summary
Three criteria are used to select the best combination of filtering process: (1) high clustering
efficiency, meaning that the number of variables whose distributions are significantly different among
subgroups is high; (2) consistency between African American and Caucasian cohorts, meaning that
the number of variants used for analysis and the ratio of patients’ number in each subgroup are
comparable between two cohorts; (3) succinctness, meaning that the number of variants used for
subtype identification is relatively low for achieving high efficiency.
Taking into consideration the above-mentioned criteria, we conclude that “logistic (cutoff p-value
= 0.05) (positive effect size) + deleterious variants” is the best choice for our population of study.
We rank selected single nucleotide polymorphisms (SNPs) (370 SNPs for African American and
217 for Caucasian) based on their p-value in the logistic regression and conduct the gene set enrichment
analysis for genes in which top 10 SNPs reside. For African American, genes for top 10 important
SNPs are COL24A1, INSL6, MTTP, ATF7IP, CUBN, SLC39A12, ZNF208, LPIN3, UTRN; COL24A1,
INSL6, MTTP, ATF7IP, CUBN, SLC39A12, and ZNF208 and are showed to have close relationship to
cardiac functions [21–26]. For Caucasian cohort, genes for top 10 important SNPs are DNHD1, ASPM,
TTC21B, GMPS-KCNAB1, HEATR1, OR10J1, and LGALS8; except for DNHD1, all other genes are
related to cardiovascular function [27–31].
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The number of significant variables in African American and Caucasian cohorts are two and six,
respectively. The box plots of these outcome variables are presented in Figures 2 and 3. Compared
with other combinations, this one uses the lowest number of variants to give a consistent ratio
of number of patients in two subgroups between the two cohorts. More specifically, Figure 2
suggests that genetic driven patient clusters tend to show differences in cardiac systolic functions.
For example, one of the main cardiac systolic indexes, global longitudinal strain (gls), shows worse
systolic mechanics in Cluster 1. Figure 3 suggests that genetic driven patient clusters tend to show
differences in both cardiac systolic and diastolic functions. For example, global longitudinal strain (gls)
and septal e’ velocity (eseptal), two main cardiac systolic and diastolic indexes, respectively, both show
worse cardiac mechanics in Cluster 1. Interestingly, Figures 2 and 3 also indicate possibly different
genotype to phenotype pathways for African American and Caucasian cohorts, which calls for more
follow-up studies.

Figure 2. Box plots of phenotypic/outcome variables whose distributions are significantly different
between two clusters in African American cohort. The p-value for gls is 0.0205 and the p-value for sr_s
is 0.0141.
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Figure 3. Box plots of phenotypic/outcome variables whose distributions are significantly different
between two clusters in Caucasian cohort. The p-values for eseptal, elateral, gls, sr_a, sr_s and sseptal
are 0.0135, 0.0465, 0.0246, 0.0151, 0.0774, 0.0879 respectively.

4. Discussion
With the phenotypic variables, researchers were able to identify more than 2 hypertension
subtypes such as borderline isolated systolic hypertension, definite isolated systolic hypertension,
isolated diastolic hypertension and definite hypertension. Our approach is more focused on exploration
on the possibility/potential to use SNP data to identify subtypes. We have expected that using SNP
data, may not allow us to get much granular subtype division as using phenotypic variables, since we
have much fewer patients compared to the number of SNPs. In the future research, we think two
possible situations will help to increase the resolution of subtype identification: (1) get more available
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patients and (2) use multi-view or integrative learning to incorporate both genetic and phenotypical
variables in the study. In addition, there are some limitations of the proposed approach. The chosen
unsupervised learning method in our research is “brunet” NMF which assumes Poisson distributed
entries of inputted matrix. The assumption holds when we aggregate variants within the same
genetic-region. However, the inputted SNP array with entries 0, 1, 2 does not strictly satisfy the model
assumption. Future work may focus on improving existing NMF algorithms for analysis of trinary
matrix. Trinary data (i.e., values 0,1,2) have a distinctive characteristic that the features (attributes)
they include have the same nature as the data they intend to account for: both are trinary. If we can
use trinary matrices (W and H) to approximate the input matrix, the clustering results will be even
more interpretable. The trinary matrix W explicitly designates the cluster memberships for data points
and the matrix H indicates the feature representations of each cluster. The other limitation is that
we have not incorporated family pedigree data as covariates in the logistic regression. Considering
the computational complexity (e.g., modeling family structure as random effect for thousands of
families will take weeks of computation), we have used age, gender, and BMI as covariates in the first
pre-processing filtering step. In future research, we will focus on the potential to incorporate pedigree
covariates into our modeling process. For other future work, we will focus on (1) considering SNPs
in regards of its associated direction (i.e., positive or negative effect size) in the logistic regression;
(2) systematically exploring the impact of deviations of practical and theoretical distributions for
NMF application on genotyping data, e.g., testing the impact on the results if imputed SNP dosage
data were used instead, with continuous variables; (3) testing our approach on an independent
dataset to further verify the main findings; (4) improving our model by starting from verified blood
pressure-associated SNPs.
5. Conclusions
In this paper, we propose a procedure that uses statistical methods to select the most informative
disease-related variants and applies suitable clustering methods to identify subgroup of patients with
similar genetic performance. The research gives promising results that selecting and analyzing
informative genetic information can result in meaningful and clinically relevant subtypes of
hypertensive patients with statistically significant difference in underlying etiology/pathophysiology
and distribution of clinical outcomes. Given the heterogeneous nature of hypertension, genetic
information learning may inform the development and trial of novel targeted therapies.
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